What is Myriad myChoice HRD?
myChoice HRD includes Tumor BRACAnalysis® for an assessment of both tumor BRCA1 and BRCA2 status as well as the tumor’s Genomic Instability Status, evaluated by three biomarkers associated with homologous recombination deficiency (HRD): LOH (loss of heterozygosity), LST (large-scale state transitions), and TAI (telomeric allelic imbalance). myChoice HRD identifies patients that are most likely to benefit from PARP inhibitors. Every patient’s cancer is unique, so their treatment should be as well. Myriad’s myChoice HRD helps physicians select the most effective treatment for their patients, minimizing the time and toxicity associated with ineffective therapies.
Learn more about Myriad’s myChoice® HRD